EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease

Viljami E Salmi iD, Annina Lyly iD, Mikko Neuvonen, Elmo Saarentaus, Mikko Niemi, Sanna Toppila-Salmi

Clinical & Experimental Allergy · 2026-01 · 56 (1) · 95-98

DOI: 10.1111/cea.70145 ↗

At a glance

Journal article in Clinical & Experimental Allergy, published online on 2025-09-18. Written by Viljami E Salmi and 5 co-authors. Institution: Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 9 references. The full text is freely available (open access, CC BY 4.0). Funded by: Jalmari ja Rauha Ahokkaan Säätiö, Suomen Allergologi- ja immunologiyhdistys, Suomen Rinologiyhdistys - Consociatio Rhinologica Fennica.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a common chronic airway inflammatory disease characterised by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and hypersensitivity to NSAIDs, including acetylsalicylic acid (ASA, aspirin), posing a significant burden on respiratory health [1]. N-ERD currently lacks reliable clinical laboratory tests, yet early diagnosis and management are essential to prevent disease progression [2]. The pathogenesis of N-ERD has been linked to dysregulation of arachidonic acid (AA) metabolism, which affects levels of pro-inflammatory lipid mediators such as leukotrienes and prostaglandins [1, 3]. ASA alters AA metabolism by inhibiting cyclooxygenase (COX) enzymes and redirecting lipid synthesis towards pro-inflammatory leukotrienes [1]. Despite extensive research into eicosanoids in N-ERD, the full spectrum of lipid mediators involved remains incompletely understood. In this study, we investigated the effect of a low dose of ASA (25 mg) on plasma and urine lipid mediator concentrations in N-ERD patients compared with healthy controls, aiming to identify novel biomarkers and deepen understanding of disease mechanisms. This study included eight consecutively recruited N-ERD patients and seven age-matched healthy controls (25-62 years). All subjects were Finnish females, selected to minimise demographic variability. ...

Subjects

Author keywords

AEALTE4N‐ERDOEAacetylsalicylic acidarachidonic acidasthmalipid mediator

Authors and institutions

  • Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
  • Department of Otorhinolaryngology, University of Eastern Finland, Joensuu and Kuopio, Finland.
  • Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
  • Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
  • Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.

ORCID profiles: Viljami E Salmi, Annina Lyly

Funding

  • Jalmari ja Rauha Ahokkaan Säätiö
  • Suomen Allergologi- ja immunologiyhdistys
  • Suomen Rinologiyhdistys - Consociatio Rhinologica Fennica
  • Yrjö Jahnssonin Säätiö
  • Väinö ja Laina Kiven Säätiö
  • Paulon Säätiö
  • Sigrid Juséliuksen Säätiö
  • Orionin Tutkimussäätiö

Cite

APA

Salmi, V. E., Lyly, A., Neuvonen, M., Saarentaus, E., Niemi, M., & Toppila-Salmi, S. (2026). Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease. Clinical & Experimental Allergy, 56(1), 95-98. https://doi.org/10.1111/cea.70145

Vancouver

Salmi VE, Lyly A, Neuvonen M, Saarentaus E, Niemi M, Toppila-Salmi S. Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease. Clinical & Experimental Allergy. 2026;56(1):95-98. doi:10.1111/cea.70145

BibTeX
@article{Salmi2026,
  author = {Salmi, Viljami E and Lyly, Annina and Neuvonen, Mikko and Saarentaus, Elmo and Niemi, Mikko and Toppila-Salmi, Sanna},
  title = {Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease},
  journal = {Clinical & Experimental Allergy},
  year = {2026},
  volume = {56},
  number = {1},
  pages = {95--98},
  doi = {10.1111/cea.70145}
}
Start for free →